A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea

This observational study tracks real-world outcomes of brigatinib — a targeted therapy already approved in South Korea — for people with advanced or metastatic non-small cell lung cancer (NSCLC) driven by a specific gene abnormality called an ALK rearrangement. ALK-positive lung cancer tends to respond well to targeted drugs, and this study collects safety and effectiveness data from everyday clinical use outside of controlled trial conditions. **You may be eligible if...** - You have ALK-positive advanced or metastatic non-small cell lung cancer - You are starting brigatinib treatment for the first time in South Korea - Your doctor has prescribed brigatinib within the locally approved label guidelines **You may NOT be eligible if...** - You are using brigatinib outside the approved Korean prescribing guidelines - You have a health condition that makes brigatinib unsafe according to its product label - You are already enrolled in another lung cancer clinical trial Talk to your doctor to see if this trial is right for you.